Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 259

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 259
---
 Stock that will be issued in connection with the Business Combination and the PIPE Equity Investment will exceed 20% of both the voting power and the shares of ParentCo Common Stock outstanding before such issuance. In addition, in the future, ParentCo will issue additional shares of ParentCo Common Stock upon exercise of the ParentCo Public Warrants and ParentCo Private Placement Warrants, in accordance with the terms of the Business Combination Agreement and as further described in this proxy statement/prospectus. There will also be shares of ParentCo Common Stock reserved for issuance under the Incentive Plan (assuming the approval of the Incentive Plan Proposal by Iris’s stockholders). For further details, see “ Proposal No. 1 — The Business Combination Proposal — The Business Combination Agreement — Consideration, ” and “ Proposal No. 3 — The Incentive Plan Proposal .”

<div align='center'>124</div>

TABLE OF CONTENTS

#### Effect of Proposal on Current Stockholders
In the event that this Proposal is not approved by Iris’s stockholders, the Business Combination cannot be consummated. In the event that this Proposal is approved by Iris’s stockholders, but the Business Combination Agreement is terminated (without the Business Combination being consummated) prior to the issuance of shares of ParentCo Common Stock pursuant to the Business Combination Agreement, ParentCo will not issue such shares of ParentCo Common Stock.

#### Required Vote for Approval
The approval of the Nasdaq Proposal requires the affirmative vote of a majority of the votes cast by stockholders present in person or represented by proxy and entitled to vote thereon at the Special Meeting (which would include presence by virtual attendance at the Special Meeting). An abstention will be counted towards the quorum requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the Nasdaq Proposal will be considered as non-discretionary) nor count as a vote cast in the Special Meeting.

The Nasdaq Proposal is conditioned on the approval and adoption of each of the Business Combination Proposal, the Incentive Plan Proposal, and the Election of the Directors Proposal.

#### Recommendation of the Iris Board

### THE IRIS BOARD UNANIMOUSLY RECOMMENDS THAT IRIS STOCKHOLDERS

#### VOTE “FOR” THE APPROVAL OF THE NASDAQ PROPOSAL.
<div align='center'>125</div>

TABLE OF CONTENTS

<div align='center'>**PROPOSAL NO.